Eva Muñoz‐Couselo

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Luping Lin, Amit J. Sabnis, Elton Chan et al. · Nature Genetics · 2015 · 553 citations · Full text

Medicine, Cancer Biology, Oncology +14

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 493 citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Peter Schmid, Roberto Salgado, Y.H. Park et al. · Annals of Oncology · 2020 · 435 citations · Full text

Medicine, Oncology, Pharmacology +14

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

Paolo A. Ascierto, Ignacio Melero, Shailender Bhatia et al. · Journal of Clinical Oncology · 2017 · 240 citations

Life Sciences, Immunology, Oncology +17

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio et al. · Journal of Clinical Oncology · 2022 · 162 citations · Full text

Medicine, Oncology, Pharmacotherapy +17